Ascendis Pharma has received approval from the US Food and Drug Administration for its therapy to treat adult patients with a hormone disorder. The Danish drugmaker’s treatment, Yorvipath, will be the only approved treatment for hypoparathyroidism in the United States after rival Takeda discontinues its injection, Natpara, at the end of the year. Yorvipath is expected to be available in the first quarter of 2025, making it a significant advancement in treating the rare endocrine disease that impacts an estimated 70,000 to 90,000 people in the US.
For years, Ascendis Pharma has been working towards bringing its treatment for hypoparathyroidism to market. With the FDA approval of Yorvipath, patients suffering from the condition will now have access to a once-daily therapy that can help normalize calcium levels in the blood and reduce the impact of low parathyroid hormone production. This development marks a significant milestone in the treatment of this rare disease, as it offers patients a much-needed solution to manage their symptoms and improve their quality of life.
The discontinuation of Takeda’s Natpara, the only other approved treatment for hypoparathyroidism in the US, further highlights the importance of Ascendis Pharma’s Yorvipath in filling the treatment gap for patients with this condition. With Natpara set to be phased out by the end of the year, Yorvipath will become the go-to therapy for patients seeking relief from the debilitating effects of hypoparathyroidism. The availability of a new treatment option signals hope for those affected by this rare disease, as they will soon have access to a treatment that can address the underlying hormonal imbalance.
According to Ascendis Pharma, hypoparathyroidism is a rare endocrine disease that results from low levels of parathyroid hormone, leading to abnormally low calcium levels in the blood and an increase of phosphorus. The condition impacts multiple organs and poses significant health risks for patients if left untreated. With the approval of Yorvipath, healthcare providers will have a new tool to effectively manage hypoparathyroidism and help patients regain control over their hormonal balance, ultimately improving their overall health and well-being.
The initial supply of Yorvipath is expected to be available in the first quarter of 2025, providing patients with a long-awaited treatment option for hypoparathyroidism. Ascendis Pharma’s dedication to bringing this therapy to market underscores the company’s commitment to addressing unmet medical needs and improving patient outcomes. As Yorvipath becomes the sole approved treatment for hypoparathyroidism in the US, it represents a major advancement in the field of endocrinology and offers a promising future for patients living with this rare disease. With the approval of Yorvipath, Ascendis Pharma has solidified its position as a leader in the development of innovative therapies for hormone disorders, paving the way for improved treatment options for patients worldwide.
